Plasminogen activator inhibitor-1: a common denominator in obesity, diabetes and cardiovascular disease.
A classical perspective of cardiovascular risk does not adequately account for all of the cardiovascular events associated with obesity and diabetes. The combination of hypertriglyceridemia, glucose intolerance and inflammation is linked with increased production of the primary inhibitor of endogenous thrombolysis, plasminogen activator inhibitor-1 (PAI-1). Recent data suggest that PAI-1 contributes directly to the complications of obesity, including type 2 diabetes, coronary arterial thrombi, and may even influence the accumulation of visceral fat. Therefore, direct inhibition of PAI-1 might not only provide a new therapeutic strategy for reducing cardiovascular risk, but may also have beneficial effects on obesity and insulin resistance.
De Taeye
Bart
B
Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Smith
L Harris
LH
Vaughan
Douglas E
DE
D000818:Animals; D002318:Cardiovascular Diseases / Q000209:etiology / Q000378:metabolism* / Q000628:therapy; D003924:Diabetes Mellitus, Type 2 / Q000209:etiology / Q000378:metabolism* / Q000628:therapy; D003925:Diabetic Angiopathies / Q000209:etiology / Q000378:metabolism* / Q000628:therapy; D006801:Humans; D009765:Obesity / Q000209:etiology / Q000378:metabolism* / Q000628:therapy; D017395:Plasminogen Activator Inhibitor 1 / Q000096:biosynthesis* / Q000235:genetics
D017395:Plasminogen Activator Inhibitor 1